ENLV Key Statistics, Chart & Performance
The current stock price of ENLV is 0.981 USD. In the past month the price increased by 17.5%. In the past year, price decreased by -16.86%.
ENLV Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ENLV. When comparing the yearly performance of all stocks, ENLV is a bad performer in the overall market: 80.11% of all stocks are doing better.
ENLV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENLV. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability.
ENLV Financial Highlights
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 43.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.66% | ||
| ROE | -72.66% | ||
| Debt/Equity | 0 |
ENLV Forecast & Estimates
8 analysts have analysed ENLV and the average price target is 13.26 USD. This implies a price increase of 1251.68% is expected in the next year compared to the current price of 0.981.
ENLV Ownership
About ENLV
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
ENLIVEX THERAPEUTICS LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 36
Phone: 97286623301
ENLIVEX THERAPEUTICS LTD / ENLV FAQ
What does ENLV do?
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
What is the current price of ENLV stock?
The current stock price of ENLV is 0.981 USD. The price increased by 0.1% in the last trading session.
Does ENLIVEX THERAPEUTICS LTD pay dividends?
ENLV does not pay a dividend.
What is the ChartMill rating of ENLIVEX THERAPEUTICS LTD stock?
ENLV has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ENLIVEX THERAPEUTICS LTD (ENLV) stock traded?
ENLV stock is listed on the Nasdaq exchange.
Should I buy ENLV stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ENLV.